Systematic Review
Published on 07 Jan 2026
Subcutaneous versus intravenous trastuzumab for HER2-positive breast cancer: a global systematic review and meta-analysis with a cost-minimization analysis from the Chinese healthcare system perspective
in Drugs Outcomes Research and Policies
- 966 views